ACI 22nd Annual Rx Drug Pricing Boot CampNew York City Bar Association
42 West 44th St
New York, NY 10036
March 20, 20241:45−2:45 p.m.
Blank Rome partner Merle M. DeLancey, Jr. will serve as a speaker at the American Conference Institute (“ACI”) 22nd Annual Rx Drug Pricing Boot Camp, being held March 20 through 21, 2024, at the New York City Bar Association in New York, New York.
ABOUT THE BOOT CAMP
The Rx Drug Pricing Boot Camp offers intensive training in the essentials and complexities of pricing calculations, rebates, and reporting under the Medicaid, Medicare, and PHS 340B Programs. With both federal and state law makers engaging in greater scrutiny of prescription drug pricing, industry professionals must stay up to date on the latest amendments to government payor programs as well as their impact on the private sector. A leading faculty of experienced practitioners will help attendees master core drug pricing concepts and calculations to gain a holistic view of how these government payor programs relate and often intersect with each other.
Merle’s session, “Unintended Consequences: Understanding the Fallout of the IRA on Government Payor Programs and the Private Sector,” will take place on Wednesday, March 20, from 1:45 to 2:45 p.m.
ABOUT THE SESSION
Topics:
- Analyzing the consequences of the Inflation Reduction Act (“IRA”) on government drug payor programs:
- Medicaid
- PHS 340B
- VA and DOD
- Understanding what the implications of the IRA are on the supply chain that inevitably affect cost and pricing
- Delving into how the private sector will be (or is) handling the IRA implementation
- Exploring how the price of drugs will vary
- Consequences for Medicare Advantage plans
- How will IRA-mandated pricing changes trickle through and affect the market to affect drug valuations as well as the economy
- Merle DeLancey, Partner, Blank Rome LLP
- James Kim, Partner, Arnold & Porter
- The Politics and Policy of Post-IRA Prescription Drug Pricing under Government Payor Programs
- IRA Implementation State of the Union: A Look Back and a Look Forward into the First Round of Drug Price Negotiations
- Focus on Part D Manufacturer Discount Program
- Simplifying Inflation Rebate Penalties under Medicare Part B and D
- Is It an Unlawful Taking? A Discussion of the Ongoing IRA Drug Price Negotiation Lawsuits
- A Look at PBMs through the Lens of the IRA: Practices and Their Legal Challenges
- Understanding How the Pricing of Biosimilars Affects Government Drug Payor Programs
- Examining the Full Impact of CMS’ Ground-Shifting New Proposed Medicaid Drug Rebate Program Rule
- Dissecting CMS’ New Guidance on Line Extensions
- In-Depth Illustration of Medicaid Drug Pricing and Rebates
- Analyzing Present and Pending State Drug Transparency Laws
- A Manufacturer’s Guide to Critical Drug Pricing and Reimbursement Considerations when Launching New Products